The global pruritus therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of chronic diseases and rising awareness about the benefits of pruritus therapeutics. The external use segment accounted for the largest share in the global market in 2018, followed by oral and injection segments. North America accounted for the largest share in 2018, followed by Europe and Asia Pacific respectively. Antihistamines are used to treat itching caused due to allergies or insect bites; corticosteroids are used for treating skin conditions such as eczema; calcineurin inhibitors are used for treating psoriasis; pruritus therapeutic drugs are used for treating various types of itchiness including atopic dermatitis, lichen planus, lichen simplex chronicus (LSC), erythromelalgia (EM), cholinergic urticaria (CU) and others. External use segment accounted for the largest share in 2018 among all types of products with a value share of 45%. Oral segment was second with a value share of 34%, followed by injection segment with a value share of 21%. North America accounted for the largest regional revenue contribution in 2018 with 36% revenue contribution from this region followed by Europe which contributed 33% revenue contribution from this region respectively. -The global Pruritus Therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period, 2016-2020. -The global Pruritus Therapeutics market is expected to reach USD 1,890 million by 2020 from USD 1,400 million in 2015. -Increasing prevalence of chronic skin diseases such as eczema and psoriasis are driving the growth of the global Pruritus Therapeutics market.
Industry Growth Insights published a new data on “Pruritus Therapeutics Market”. The research report is titled “Pruritus Therapeutics Market research by Types (Antihistamines, Corticosteroids, Calcineurin Inhibitors, Other, Pruritus Therapeutic), By Applications (External Use, Oral, Injection), By Players/Companies J&J, Abbott, Amgen, LEO Pharma, Novartis, Bayer, Pfizer, UCB Pharma, GlaxoSmithKline, Galderma, Huapont, Pruritus Therapeutic”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pruritus Therapeutics Market Research Report
By Type
Antihistamines, Corticosteroids, Calcineurin Inhibitors, Other, Pruritus Therapeutic
By Application
External Use, Oral, Injection
By Companies
J&J, Abbott, Amgen, LEO Pharma, Novartis, Bayer, Pfizer, UCB Pharma, GlaxoSmithKline, Galderma, Huapont, Pruritus Therapeutic
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Pruritus Therapeutics Market Report Segments:
The global Pruritus Therapeutics market is segmented on the basis of:
Types
Antihistamines, Corticosteroids, Calcineurin Inhibitors, Other, Pruritus Therapeutic
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
External Use, Oral, Injection
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- J&J
- Abbott
- Amgen
- LEO Pharma
- Novartis
- Bayer
- Pfizer
- UCB Pharma
- GlaxoSmithKline
- Galderma
- Huapont
- Pruritus Therapeutic
Highlights of The Pruritus Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antihistamines
- Corticosteroids
- Calcineurin Inhibitors
- Other
- Pruritus Therapeutic
- By Application:
- External Use
- Oral
- Injection
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pruritus Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pruritus Therapeutics is a clinical stage biotechnology company focused on the development of novel therapeutics to treat pruritus, or itch. The company's lead product candidate, PT-1002, is a novel oral small molecule drug that targets and inhibits the activity of histamine receptors.
Some of the major companies in the pruritus therapeutics market are J&J, Abbott, Amgen, LEO Pharma, Novartis, Bayer, Pfizer, UCB Pharma, GlaxoSmithKline, Galderma, Huapont, Pruritus Therapeutic.
The pruritus therapeutics market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pruritus Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pruritus Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pruritus Therapeutics Market - Supply Chain
4.5. Global Pruritus Therapeutics Market Forecast
4.5.1. Pruritus Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pruritus Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pruritus Therapeutics Market Absolute $ Opportunity
5. Global Pruritus Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pruritus Therapeutics Market Size and Volume Forecast by Type
5.3.1. Antihistamines
5.3.2. Corticosteroids
5.3.3. Calcineurin Inhibitors
5.3.4. Other
5.3.5. Pruritus Therapeutic
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pruritus Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pruritus Therapeutics Market Size and Volume Forecast by Application
6.3.1. External Use
6.3.2. Oral
6.3.3. Injection
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pruritus Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pruritus Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pruritus Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pruritus Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pruritus Therapeutics Demand Share Forecast, 2019-2026
9. North America Pruritus Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pruritus Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pruritus Therapeutics Market Size and Volume Forecast by Application
9.4.1. External Use
9.4.2. Oral
9.4.3. Injection
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pruritus Therapeutics Market Size and Volume Forecast by Type
9.7.1. Antihistamines
9.7.2. Corticosteroids
9.7.3. Calcineurin Inhibitors
9.7.4. Other
9.7.5. Pruritus Therapeutic
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pruritus Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Pruritus Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pruritus Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pruritus Therapeutics Market Size and Volume Forecast by Application
10.4.1. External Use
10.4.2. Oral
10.4.3. Injection
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pruritus Therapeutics Market Size and Volume Forecast by Type
10.7.1. Antihistamines
10.7.2. Corticosteroids
10.7.3. Calcineurin Inhibitors
10.7.4. Other
10.7.5. Pruritus Therapeutic
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pruritus Therapeutics Demand Share Forecast, 2019-2026
11. Europe Pruritus Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pruritus Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pruritus Therapeutics Market Size and Volume Forecast by Application
11.4.1. External Use
11.4.2. Oral
11.4.3. Injection
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pruritus Therapeutics Market Size and Volume Forecast by Type
11.7.1. Antihistamines
11.7.2. Corticosteroids
11.7.3. Calcineurin Inhibitors
11.7.4. Other
11.7.5. Pruritus Therapeuic
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pruritus Therapeutics Demand Share, 2019-2026
12. Asia Pacific Pruritus Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pruritus Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pruritus Therapeutics Market Size and Volume Forecast by Application
12.4.1. External Use
12.4.2. Oral
12.4.3. Injection
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pruritus Therapeutics Market Size and Volume Forecast by Type
12.7.1. Antihistamines
12.7.2. Corticosteroids
12.7.3. Calcineurin Inhibitors
12.7.4. Other
12.7.5. Pruritus Therapeutic
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pruritus Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Pruritus Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pruritus Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pruritus Therapeutics Market Size and Volume Forecast by Application
13.4.1. External Use
13.4.2. Oral
13.4.3. Injection
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pruritus Therapeutics Market Size and Volume Forecast by Type
13.7.1. Antihistamines
13.7.2. Corticosteroids
13.7.3. Calcineurin Inhibitors
13.7.4. Other
13.7.5. Pruritus Therapeutic
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pruritus Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pruritus Therapeutics Market: Market Share Analysis
14.2. Pruritus Therapeutics Distributors and Customers
14.3. Pruritus Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. J&J
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Abbott
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Amgen
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. LEO Pharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bayer
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Pfizer
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. UCB Pharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. GlaxoSmithKline
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Galderma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Huapont
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Pruritus Therapeutic
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook